FDA Toughens Warnings On MRI Contrast Agents
The U.S. Food and Drug Administration will now require gadolinium-based contrast agents used during MRI procedures to carry updated warnings on their labels indicating the risk that certain patients with kidney...To view the full article, register now.
Already a subscriber? Click here to view full article